Lantheus Holdings, Inc. to acquire Life Molecular Imaging, enhancing growth profile with competitive advantages.
From GlobeNewswire: 2025-01-13 00:05:00
Lantheus Holdings, Inc. has announced the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., for $350 million upfront and up to $400 million in potential earn-out and milestone payments. The acquisition includes Neuraceq®, an F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease. This transaction is expected to enhance Lantheus’ growth profile and establish a commercial Alzheimer’s disease franchise. Lantheus plans to utilize Life Molecular’s resources to accelerate the development and commercialization of their pipeline. The acquisition is expected to be accretive to adjusted EPS within the first 12 months.
The acquisition of Life Molecular Imaging by Lantheus Holdings, Inc. will advance Lantheus’ radiopharmaceutical leadership by adding Alzheimer’s radiodiagnostic commercial infrastructure and expanding their pipeline. Neuraceq®, a globally approved F-18 radioactive diagnostic agent used for PET imaging of the brain to estimate β-amyloid neuritic plaque density, will also enhance Lantheus’ growth profile. The transaction is expected to be accretive to Lantheus’ adjusted earnings per share within the first 12 months. Lantheus will host a conference call on January 13, 2025, at 8:30 AM EST to discuss the acquisition.
The acquisition of Life Molecular Imaging by Lantheus is expected to immediately enhance Lantheus’ near and long-term growth profile, with the addition of Neuraceq, a globally approved F-18 radioactive diagnostic agent for PET imaging of the brain. The transaction is also set to establish a commercial Alzheimer’s disease franchise. Lantheus plans to leverage Life Molecular’s resources, including R&D capabilities and international presence, to accelerate the development, advancement, and commercialization of their combined company’s pipeline. The acquisition is projected to be accretive to Lantheus’ Adjusted Earnings Per Share within the first 12 months.
Read more at GlobeNewswire: Lantheus to Acquire Life Molecular Imaging for an Upfront